Alto Neuroscience (ANRO) Q3 2024 earnings summary

Executive summary

• Clinical-stage biopharma focused on precision psychiatry, with five clinical-stage assets targeting MDD, bipolar depression, and schizophrenia, all characterized by brain-based biomarkers.

• ALTO-100 Phase 2b in MDD did not meet its primary endpoint; however, adjunctive treatment subgroup showed a clinically meaningful effect, supporting continued development in bipolar depression.

• Ongoing Phase 2b trials for ALTO-100 (bipolar depression) and ALTO-300 (MDD), with topline data expected in 2026 and 1H 2025, respectively.

• Net losses continue as the company invests in R&D and expands operations post-IPO.

Financial highlights

• Net loss for Q3 2024 was $16.8 million, compared to $9.1 million in Q3 2023; net loss for the nine months ended September 30, 2024 was $46.2 million, up from $25.1 million year-over-year.

• Research and development expenses rose to $13.1 million in Q3 2024 (from $8.0 million in Q3 2023) and $36.2 million for the nine months (from $20.6 million year-over-year).

• General and administrative expenses increased to $5.8 million in Q3 2024 (from $1.8 million in Q3 2023) and $15.4 million for the nine months (from $5.4 million year-over-year).

• Cash, cash equivalents, and restricted cash totaled $182.2 million as of September 30, 2024, up from $82.5 million at year-end 2023, bolstered by $133.0 million in net IPO proceeds.

• Weighted-average shares outstanding for Q3 2024 were 26.96 million, reflecting the IPO and conversion of preferred stock.

Outlook and guidance

• Cash runway expected to fund operations into 2027, based on current plans and spending assumptions.

• Anticipates continued increases in operating expenses as clinical programs advance and as the company builds out commercialization and public company infrastructure.

• Additional capital will be required to complete development and commercialization of product candidates; future funding may come from equity, debt, grants, or collaborations.